# Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2021

- Company: [Can-Fite BioPharma Ltd.](/companies/canf.md) (CIK 1536196)
- Form: 20-F
- Filed: 2022-03-24
- Accepted by EDGAR: Mar 24, 2022, 09:38 ET
- Period: 2021-12-31
- Accession: 0001213900-22-014672
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1536196/000121390022014672/f20f2021_canfitebio.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1536196/000121390022014672/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2021-01-01 to 2021-12-31 | $853.0k | us-gaap:Revenues |
| Research and development | 12 months, 2021-01-01 to 2021-12-31 | $9.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 12 months, 2021-01-01 to 2021-12-31 | −$12.8m | us-gaap:OperatingIncomeLoss |
| Net income | 12 months, 2021-01-01 to 2021-12-31 | −$12.6m | us-gaap:NetIncomeLoss |
| Operating cash flow | 12 months, 2021-01-01 to 2021-12-31 | −$9.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2021-01-01 to 2021-12-31 | $11.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months, 2021-01-01 to 2021-12-31 | $2.6m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | at 2021-12-31 | $4.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-12-31 | $20.1m | us-gaap:AssetsCurrent |
| Total assets | at 2021-12-31 | $20.3m | us-gaap:Assets |
| Current liabilities | at 2021-12-31 | $2.7m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2021-12-31 | $14.4m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2021-12-31 | 815,746,293 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1536196/000121390022014672/f20f2021_canfitebio.htm

Filed Mar 24, 2022.
Source: SEC EDGAR, the filing index for accession 0001213900-22-014672. Last ingested by Listed: Nov 2, 2026, 07:04 ET. No prices; not investment advice.